Brought to you by
CAR T-cell therapies are emerging anti-cancer treatments, whereby the patient’s immune cells are engineered to express chimeric antigen receptors (CARs) on their surface. Wider adoption of this therapeutic modality would benefit from innovative technologies that can improve the characterization of raw material quality attributes (MQA) and final product quality attributes (PQA).
Here, we present the development of a sensitive proteomic method to characterize CAR T cells using SWATH™ technology. We evaluated key steps of the data acquisition, from separation to detection, to enhance the sensitivity by data dependent and independent methods.
The data represent an instrument benchmarking that will ultimately be used as performance qualification metrics to assure instrument control for biologically relevant decision making of CAR T proteomic samples.
By attending this webinar, you will learn: